EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

High power short duration versus low power long duration ablation in patients with atrial fibrillation: A meta‐analysis of randomized trials

Antonio Parlavecchio iD, Giampaolo Vetta iD, Giovanni Coluccia iD, Lorenzo Pistelli, Rodolfo Caminiti, Manuela Ajello, Michele Magnocavallo, Giuseppe Dattilo, Rosario Foti, Scipione Carerj, Pasquale Crea, Gian Battista Chierchia und 3 weitere

Pacing and Clinical Electrophysiology · 2023

DOI: 10.1111/pace.14838 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Pacing and Clinical Electrophysiology, 2023. Verfasst von Antonio Parlavecchio und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Cryosurgery, Pulmonary Veins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐power‐short‐duration (HPSD) radiofrequency (RF) ablation is a viable alternative to low‐power‐long‐duration (LPLD) RF for pulmonary vein isolation (PVI). Nevertheless, trials showed conflicting results regarding atrial fibrillation (AF) recurrences and few data concerning complications. Therefore, we conducted a meta‐analysis of randomized trials comparing HPSD versus LPLD.

Methods

We systematically searched the electronic databases for studies published from inception to March 31, 2023 focusing on HPSD versus LPLD. The study endpoints were AF recurrence, procedural times and overall complications.

Results

Five studies enrolling 424 patients met the inclusion criteria (mean age 61.1 years; 54.3% paroxysmal AF; mean LVEF 58.2%). Compared to LPLD, HPSD showed a significantly lower AF recurrence rate [16.3% vs. 30,1%; RR: 0.54 (95% CI: 0.38–0.79); p = 0.001] at a mean 10.9 months follow‐up. Moreover, HPSD led to a significant reduction in total procedural time [MD: −26.25 min (95%CI: −42.89 to −9.61); p = 0.002], PVI time [MD: −26.44 min (95%CI: −38.32 to −14.55); p < 0.0001], RF application time [MD: −8.69 min (95%CI: −11.37 to −6.01); p < 0.00001] and RF lesion number [MD: −7.60 (95%CI: −10.15 to −5.05); p < 0.00001]. No difference was found in either right [80.4% vs. 78.2%; RR: 1.04 (95% CI: 0.81–1.32); p = 0.77] or left [92.3% vs. 90.2%; RR: 1.02 (95% CI: 0.94–1.11); p = 0.58] first‐pass isolation and overall complications [6% vs. 3.7%; RR: 1.45 (95%CI: 0.53–3.99); p = 0.47] between groups.

Conclusion

In our metanalysis of randomized trials, HPSD ablation appeared to be associated to a significantly improved freedom from AF and shorter procedures, without increasing the risk of complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationCryosurgeryPulmonary VeinsHumansMiddle AgedRandomized Controlled Trials as TopicRecurrenceTime FactorsTreatment Outcome

Stichwörter der Autor:innen

HPSDLPLDatrial fibrillationpulmonary vein isolationradiofrequency

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy.
  • Cardiology Unit, "Card. G. Panico" Hospital, Via S. Pio X, Tricase, Italy.
  • Arrhythmology Unit, Ospedale San Giovanni Calibita, Fatebenefratelli Isola Tiberina, Via Ponte Quattro Capi 39, Rome, Italy.
  • San Vincenzo Hospital, Taormina, Italy.
  • Heart Rhythm Management Centre, Postgraduate Program in C ardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, European Reference Networks Guard-Heart, Brussels, Belgium.

ORCID-Profile: Antonio Parlavecchio, Giampaolo Vetta, Giovanni Coluccia, Pietro Palmisano

Zitieren

APA

Parlavecchio, A., Vetta, G., Coluccia, G., Pistelli, L., Caminiti, R., Ajello, M., Magnocavallo, M., Dattilo, G., Foti, R., Carerj, S., Crea, P., Chierchia, G. B., de Asmundis, C., Della Rocca, D. G., & Palmisano, P. (2023). High power short duration versus low power long duration ablation in patients with atrial fibrillation: A meta‐analysis of randomized trials. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.14838

Vancouver

Parlavecchio A, Vetta G, Coluccia G, Pistelli L, Caminiti R, Ajello M, et al. High power short duration versus low power long duration ablation in patients with atrial fibrillation: A meta‐analysis of randomized trials. Pacing and Clinical Electrophysiology. 2023. doi:10.1111/pace.14838

BibTeX
@article{Parlavecchio2023,
  author = {Parlavecchio, Antonio and Vetta, Giampaolo and Coluccia, Giovanni and Pistelli, Lorenzo and Caminiti, Rodolfo and Ajello, Manuela and Magnocavallo, Michele and Dattilo, Giuseppe and Foti, Rosario and Carerj, Scipione and Crea, Pasquale and Chierchia, Gian Battista and de Asmundis, Carlo and Della Rocca, Domenico Giovanni and Palmisano, Pietro},
  title = {High power short duration versus low power long duration ablation in patients with atrial fibrillation: A meta‐analysis of randomized trials},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2023},
  doi = {10.1111/pace.14838}
}
Kostenlos starten →